| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | QL-XII-61 | GDSC1000 | pan-cancer | AAC | -0.008 | 0.9 |
| mRNA | tubastatin A | GDSC1000 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | LBW242 | CCLE | pan-cancer | AAC | -0.0082 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | 0.0055 | 0.9 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.0063 | 0.9 |
| mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | neopeltolide | CTRPv2 | pan-cancer | AAC | -0.012 | 0.9 |